top of page


MedSIR to present results of clinical trials PHERGain and PARSIFAL at ASCO 2020

Updated: Aug 13, 2021

The American Society of Clinical Oncology (ASCO) organizes one of the largest gatherings of medical professionals annually, where over 40,000 participants from around the world gather to present and discuss the latest advances in oncology.

This week, despite the current circumstances, the 56th edition of ASCO will be held in a virtual format so that oncologists and clinical scientists have the opportunity to share the results of their work with people around the globe.

We invite you to join us on Friday, May 29th at 15:00 GMT-5 (22:00 GMT+2) (ASCO registration)

to hear MedSIR founders, Dr. Antonio Llombart, Head of Clinical Oncology at the Arnau Vilanova hospital in Valencia and Dr. Javier Cortés, Head of the Breast Cancer Program at IOB Quirónsalud and ​​Clinical Researcher at the Institute of Oncology in Vall Hebrón present the results of two clinical trials sponsored by MedSIR: PHERGain and PARSIFAL.

PHERGain is a randomized phase II clinical trial with 356 patients enrolled from a total of 7 countries and 45 different recruiting sites. It evaluates a chemotherapy-free treatment consisting in the combination of trastuzumab and pertuzumab in HER2[+] early breast cancer patients. The two main endpoints of this study are to assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) in this cohort of patients, and their predictive value for pathologic complete response. As a secondary endpoint, the study will evaluate the use of PET response-adapted strategy to assess invasive disease-free survival. This is very important as PET imaging is widely available, so being able to utilize this tool to de-escalate therapy for people with breast cancer would be very beneficial for both patients and oncologists.

Our PARSIFAL study, which has just ended, was a randomised phase II clinical trial for ER[+]/HER2[-] advanced breast cancer. It explored the optimal endocrine agent to combine with palbociclib in the first-line endocrine-sensitive scenario. A total of 486 patients from 48 hospitals in 7 different countries were recruited for this study with the objective to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole, and to assess progression-free survival in different prespecified subgroups.

It is our mission at MedSIR to advance research and share our findings with the global oncology community, in order to ensure the optimal care and treatment of patients with cancer. We hope that you will join us Friday as our experts present these innovative trial’s first conclusions.




bottom of page